Human vaccination with BioThrax TM requires six injections followed by annual boosters. This makes it difficult for the compliance of the immunization program and underscores the need for development of a new and optimized vaccination protocol. Current research aims to demonstrate the proof of concept to develop a needle-free mucosal immunization protocol using a murine anthrax model. A/J mice were immunized with BioThrax TM via an intranasal route. Sera, saliva, vaginal, and nasal washes were evaluated for protective antigen (PA) specific antibody responses by ELISA. Antigen-specific, antibody-secreting lymphocytes were measured by ELISPOT. Sera neutralization antibody titers were determined by in vitro anthrax lethal toxin (Letx) neutralization assay. Immunized animals were challenged by a lethal dose of Bacillus anthracis Sterne spores to determine the efficacy of the vaccination. Nasal mucosal immunization with BioThrax TM elicited robust serum and mucosal antibody responses against PA. The antigen specific antibodies neutralized anthrax Letx, as demonstrated by in vitro neutralization assays. Two doses of intranasal BioThrax TM were sufficient to completely protect A/J mice against challenge with 100 × LD 50 B. anthracis Sterne spores. The data suggests that intranasal administration may be an effective immunization modality for an improved immunization program against anthrax.
Introduction
Anthrax is caused by the Gram-positive, spore-forming, rod-shaped bacterium Bacillus anthracis [1] . Intentional dissemination of B. anthracis spores by bioterrorists recently resulted in 11 cases of cutaneous anthrax and 11 cases of inhalational anthrax, including five deaths in the US [2, 3] . This bioterror threat underscores the urgent need for the development of an improved immunization program against anthrax.
Protective antigen (PA), one of the anthrax toxin components, has been shown to be an essential component of an anthrax vaccine [4, 5] . Interestingly, researchers have * Corresponding author. Tel.: +1 585 2751003; fax: +1 585 4739573.
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found that anti-PA antibody specific immunity has antispore activity and might play a role in impeding the early stages of infection with B. anthracis spores [6] . The current US human anthrax vaccine, BioThrax TM (Anthrax Vaccine Adsorbed/AVA, BioPort Corporation, Lansing, MI), consists of aluminum hydroxide-adsorbed supernatant material from fermentor cultures of a toxigenic, non-encapsulated strain of B. anthracis. It contains primarily protective antigen and undefined quantities of lethal factor (LF) and edema factor (EF), the other two anthrax toxin components. Human vaccination with AVA requires six immunizations followed by annual boosters [7, 8] . One percent and 3.6% local adverse events in humans occur with vaccine injections [9] .
In addition to PA, LF, and EF may play an important role in providing immunity [10] [11] [12] [13] [14] . Immunization with solely somatic components of B. anthracis, such as surface polysaccharides and cell-associated antigens EA1 and EA2, has not provided protective immunity [15] . However, studies of spore vaccines suggest that some other B. anthracis antigens may contribute in a significant manner to protective immunity [16, 17] .
Although neutralizing antibodies to anthrax toxins addresses the toxemia component of anthrax disease, immune responses to additional virulence factors or somatic antigens in the spore and vegetative cell may be critical to the development of complete immunity to anthrax exposure. An improved vaccine should be designed to target both toxemia and septicemia [4, 18] . It has been reported that the BioThrax TM products contain some somatic antigens and are able to evoke host immune responses against the somatic components of B. anthracis [19] . Therefore, BioThrax TM may be able to target both toxemia and septicemia. Thus, BioThrax TM may have better protective efficacy against anthrax in comparison with that of the recombinant PA (rPAbased) vaccine currently under development.
Evidence has shown that mucosal, but not parenteral, immunization induces immune responses in both systemic and secretory immune compartments [20] . Thus, a vaccine administered parenterally, such as the BioThrax TM vaccine, most likely would not induce mucosal immunity against inhalational anthrax. Therefore, we have studied intranasal mucosal immunization with human anthrax vaccine and demonstrated that this immunization method may provide an efficacious and more acceptable vaccine strategy to prevent multi-type anthrax disease states.
Materials and methods

Materials
Protective antigen and lethal factor (LF) were purchased from List Biological Laboratories, Inc. (Campbell, CA). Biothrax TM vaccine (AVA) was produced by BioPort Corporation (Lansing, MI). B. anthracis Sterne strain spores were from an anthrax spore vaccine, which is a viable suspension of the Sterne strain 34F2 spores in saponin (Colorado Serum Company, Denver, CO). Mouse monocyte macrophage cell line J774A.1 was purchased from the American Type Culture Collection (Manassas, VA).
Animals, treatments, and sample collection
Female A/J mice at 6-8 weeks old were purchased from Jackson Laboratory (Bar Harbor, ME) and housed under BSL2 pathogen-free conditions in the vivarium facility at the University of Rochester Medical Center. The animal research herein reported was conducted in facilities with programs accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. Experiment 1. After anesthesia with katamine and xylazine, mice (eight mice/group) were immunized intranasally by instillation with different doses of BioThrax TM (7.5, 15 , and 30 l) in treatment groups or 30 l physiological saline in control groups. Animals were immunized once (week 0), twice (weeks 0, 3), or three times (weeks 0, 3, and 5). Animal sera were obtained by retro-orbital bleeding at weeks 0, 3, 5, 7 and stored at −20 • C until use. Immunized animals were challenged by subcutaneous injection with a dose of approximately 100 times the 50% lethal dose (LD 50 ) [21] , 1.85 × 10 5 spores of B. anthracis Sterne, 8 weeks after the first immunization when serum anti-PA antibody level was at its peak time after three time immunizations.
The animals were monitored four times a day for 1 week after spore challenge and twice a day thereafter. The endpoint for the spore challenge experiment was the occurrence of severe anthrax symptoms or 2 weeks after spore injection. Any animals that developed severe symptoms of anthrax, such as ruffled coat, hunching, shivering, uncoordinated movements, dehydration, respiratory difficulties, massive edema, and skin lesions, were euthanized promptly during the 2 weeks.
Experiment 2. Mice were allotted into treatment groups A, B, and C (six mice/group) and the corresponding control groups A', B', and C' (4 mice/group), respectively. The animals were immunized by the intranasal route with 30 l of BioThrax TM once (week 0) in group A, twice (weeks 0, 3) in group B, and three times (weeks 0, 3, 5) in group C. The control groups were administered 30 l physiological saline accordingly. Saliva, nasal wash, vaginal wash, and spleen samples were collected at week 3 from groups A and A', at week 5 from groups B and B', and at week 7 from groups C and C'. After the animals were injected intraperitoneally with 10 g carbachol (Sigma, St. Louis, MO) in 0.1 ml 0.9% NaCl solution to stimulate flow, saliva were collected by means of a 200-pld pipettor fitted with a plastic tip [22] . After collection of saliva, the animals were sacrificed. A 50 l 0.9% NaCl solution was instilled into the vaginal and nasal cavities to collect vaginal and nasal wash samples, respectively. Then, spleens were obtained to isolate lymphocytes for ELISPOT assay.
Quantitative ELISA for measurement of serum antibody concentration
Serum anti-PA IgG, IgG1, IgG2a, and IgA antibody concentrations were determined using ELISA Quantitation Kits (Bethel Lab. Inc., Montgomery, TX) with a modified procedure. Briefly, 96-well flat-bottom immuno plates (Nalge Nunc International, Rochester, NY) were coated with 1 g/well capture antibodies (goat anti-mouse IgG-, or IgG1-, or IgG2a-, or IgA-affinity purified) for standard curve or 100 ng/well PA (List Biological Laboratories, Inc.) for sera samples antibody concentration measurement in 100 l coating buffer (0.05 M carbonate-bicarbonate buffer, pH 9.6) and incubated overnight at 4 • C. The plates were then washed five times with washing buffer (0.05% Tween 20 in PBS) and blocked with 200 l PBS (pH 7.4) containing 1% bovine serum albumin (BSA) for 1 h at room temperature. After five washes, 100 l serial dilutions of reference serum containing the given amount of mouse antibodies (for standard curve) or 1:100 dilutions of mouse sera samples in PBS (pH 7.4) containing 0.05% Tween 20 and 1% BSA were added to each well, and this was incubated for 2 h at 37 • C. The plates were washed with washing buffer five times and incubated with 100 l/well of 1:10,000 dilution of goat anti-mouse IgG, IgG1 or IgG2a conjugated to alkaline phosphates for 1 h at room temperature. Unbound antibodies were removed by washing five times with washing buffer, and the bound antibody was detected following incubation with pnitrophenylphosphate phosphatase substrate system (KPL, Gaithersburg, MD) for 30 min. The reaction was stopped by adding 0.5 M EDTA, and the absorbance values were obtained using a Dynatech MR4000 model microplate reader at 405 nm. A standard curve was generated for each set of samples, and serum antibody concentrations were calculated in accordance to the standard curve.
Measurement of anthrax lethal toxin neutralizing antibody titer
The Letx (LF + PA) neutralization was measured by the ability of sera to neutralize the cytotoxicity of Letx for J774A.1 mouse macrophage cells. This colorimetric toxin neutralization assay (TNA) was performed as described previously, except that pooled sera (two mice/pool) were used in the assays [14] . The Letx-neutralizing antibody titers of individual serum, calculated by linear regression analysis, were expressed as the reciprocal of the antibody dilution preventing 50% of cell death [23] .
Determination of antibody forming cells (AFCs) by enzyme-linked immunospot assay (ELISPOT)
ELISPOT was performed as previously described with modifications [20, 24] . Multiscreen-IP plates (Millipore Corp., Billerica, MA) were pre-wetted with 35% ethanol, washed with PBS, and coated with either PA or BSA (Promega, Madison, WI) at 5 g/ml, and incubated overnight at 4 • C. The plates were then decanted and washed with PBS. A 200 l of Rg-10 medium containing RPMI 1640 (with l-glutamine but no phenol red from Invitrogene), antibiotics (100 IU Penicillin, 100 g/ml Streptomycin, and 0.25 g/ml Amphotericin B), 10% heat-inactivated FBS (Hyclone, Logan, UT), and 50 M ␤-mercaptoethanol were added into each well and incubated at 37 • C and 5% CO 2 for at least 2 h until use. After the control (four mice/group) or immunized mice (six mice/group) were sacrificed, their spleens were collected and placed in ice-cold Rg-10 medium. Spleens were mashed through two meshed screens, collected in 15 ml Rg-10, and centrifuged at 1000 RPM for 10 min at room temperature. To lyse the red blood cells, the pellet was resuspended into 1 ml sterile ACK solution (150 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.3). This suspension was raised to 25 ml with Rg-10 and then centrifuged as above. The pellet of lymphocytes was resuspended and centrifuged three more times and finally resuspended into 1.5 ml Rg-10. Cells were counted and tested for viability using the trypan blue exclusion assay. Cells were appropriately diluted so that 5 × 10 5 cells per well could be added by delivering 100 l cells/well. Cells were then incubated at 37 • C, 5% CO 2 for 5 h, removed, and washed five times with PBS + 0.1% Tween (PBST). HRP-conjugated antibodies goat anti-mouse IgA and IgG (Zymed/Invitrogen) along with IgG1 and IgG2a (Bethyl Laboratories, Montgomery, TX) were mixed in PBS + 0.1% Tween + 2% BSA (PBSTB) and filtered with an Acrodisc 25 mm PF filter and added to wells at 1 g/ml. The plates and antibody were incubated overnight at 4 • C. The following morning, the plates were washed four times with PBST and then once with PBS. A 50 l HRP substrate TrueBlue TM (KPL, Gaithersburg, MD) was added according to manufacturer's protocol. The plates were rinsed and allowed to dry for at least 1 day, read on a CTL Immunospot reader (CTL, Cleveland OH), and analyzed using the Immunospot 3 program (CTL). Each well was run in triplicate, and the negative control (IP plate coated with BSA) was subtracted from the experimental during analysis.
Statistical analysis
Antibody concentration and ELISPOT data among different groups at different time points were compared and analyzed using the Fisher LSD test, ANOVA; survival analysis was performed by Time Log-Rank Test. In comparing groups, P < 0.05 were considered significantly different. All statistical analysis was performed using Statistica 7.1 software from StatSoft, Inc. (Tulsa, OK). Table 1 summarizes serum antibody responses against PA after single and multiple immunizations with different dosages of BioThrax TM . As expected, the anti-PA serum antibody responses appear dose-dependent. A single intranasal immunization with BioThrax TM even at the lowest dosage tested (7.5 l) elicited robust anti-PA IgG, IgG1, and IgG2a response 3 weeks after immunization in comparison with the control (P < 0.05). The antibody levels reached their peaks at about 5 weeks after vaccine inoculation. The rise in antigen specific IgG1 and IgG2a after intranasal immunization with BioThrax TM suggested that both Th2 and Th1 immune responses, with predominant Th2 responses against PA were elicited (values of IgG2a/IgG1 < 1.0). The 15 and 30 l dosage groups produced significantly high anti-PA total IgG responses compared to the 7.5 l dosage group at week 5. However, no significant difference was found in the anti-PA total IgG responses between the 15 and 30 l dosage groups (P = 0.079). In order to show that booster immunization could enhance the anti-PA antibody responses, we also immunized animals two and three times ( Table 1 ). The first booster immunization with all three dosages significantly enhanced anti-PA IgG, IgG1, and IgG2a responses at week 5 compared to a single immunization (P < 0.05); the second booster further significantly enhanced anti-PA IgG, IgG1, and IgG2a immune responses at week 7 (P < 0.05).
Results
Sera antibody response after intranasal immunization with BioThrax TM
Anti-PA IgA in mucosal secretions
To determine if intranasal mucosal immunization with BioThrax TM is able to elicit antigen-specific mucosal immunity, we measured secretory anti-PA antibody levels in saliva, nasal, and vaginal washes from immunized animals. Anti-PA IgA concentrations in mucosal secretions after one-, two-, and three-time immunization with a dosage of 30 l vaccine are shown in Fig. 1 . Significant mucosal anti-PA IgA responses after a single intranasal immunization with BioThrax TM were observed (week 3), and booster immunizations (week 5 and 7) further significantly enhanced mucosal IgA responses (P < 0.05).
Antigen specific antibody secreting cells (ASC) by ELISPOT assay
A significant increase in the number of IgG, IgG1, and IgG2a antigen specific antibody secreting lymphocytes was measured upon stimulation with PA (Fig. 2) , consistent with the ELISA data shown in Table 1 . A high percentage of PA-specific IgA secreting cells were also identified, indicating that mucosal IgA responses were elicited by intranasal immunization. The number of PA-specific, antibodysecreting cells increased when booster immunizations were given. Fig. 2 . Determination of PA specific antibody forming cells by ELISPOT assay. After mice were immunized intranasally with 30 l of BioThrax TM once (week 0), twice (weeks 0, 3), or three times (weeks 0, 3, 5), they were sacrificed for collection of spleen tissue samples for ELISPOT assay (BioThrax TM , n = 6; control, n = 4).
In vitro protection against anthrax lethal toxin
Anti-PA antibodies in the sera were capable of neutralizing anthrax Letx using an in vitro protection assay. As shown in Fig. 3 (inset part) , a single intranasal immunization with a dosage of 7.5, 15, or 30 l of BioThrax TM resulted in Letx neutralization antibody titers (geomean) up to 11, 32, and 160, respectively. A dose-dependent toxin neutralization antibody response was observed, and booster immunization further significantly enhanced Letx neutralization antibody titers to 38, 1280, and 1522, respectively (P < 0.05), as did a second booster (Fig. 3) .
Protective immunity elicited by intranasal immunization with BioThrax TM
A single intranasal immunization with 7.5, 15, and 30 l BioThrax TM partially protected mice against the anthrax spore challenge (Fig. 4A) , with protection rates of 50, 50, and 62%; one additional booster immunization resulted in 100% protection with the 15 and 30 l immunization dosages, while one booster immunization with 7.5 l vaccine raised the protection rate from 50 to 62% (Fig. 4B) . A second booster immunization in 7.5 l immunization dosage group increased the protection rate from 62 to 85% (Fig. 4C ).
Discussion
We have shown that an intranasal immunization with BioThrax TM is capable of eliciting significant Th2 and Th1 immune responses, with predominant Th2 responses, against Fig. 3 . Neutralization of anthrax lethal toxin by sera from mice immunized with BioThrax TM . Serial two-fold dilutions of sera were pre-incubated with recombinant LF and PA, and then added to J774A.1 mouse macrophage cells. The cell viability was measured by colorimetric toxin neutralization assay (TNA). The neutralization titers were expressed as the reciprocal of antibody dilution preventing 50% of cell death (n = 4, 2 mice/sera pool, 4 pools). PA and that the anti-PA antibodies are capable of neutralizing the toxicity of Letx. Intranasal mucosal immunization with BioThrax TM elicited mucosal secretory IgA responses as well. This resulted in host protective immunity against B. anthracis spore challenge. The protective immune response appeared to be dose-dependent and boostable. This is the first report to show the protective efficacy of needle-free intranasal mucosal immunization with 1-3 doses of human anthrax vaccine.
B. anthracis spores may invade the host via the mucosal route and cause inhalational anthrax which is the major threat when B. anthracis spores are used as a biologic weapon. Previous studies suggest that the upper respiratory tract and other mucosal tissues are affected by inhalational anthrax [2, [25] [26] [27] . Therefore, host immunity at the mucosal sites of entry may be effective for protection against inhalational anthrax. Previous studies by Welkos et al. have demonstrated that anti-PA antibodies stimulate spore uptake and interfere with germination in macrophage culture and animal models [6, 28] . This suggests a potentially protective role of anti-PA antibodies at mucosal surfaces against anthrax spore infection. Mucosal, but not parenteral, immunization with PA induces immune responses in both systemic and secretory immune compartments [20] . Our study demonstrates that intranasal immunizations with BioThrax TM elicit robust mucosal and systemic antibody responses against PA. However, more experiments are needed to determine if intranasal immunization with BioThrax TM can provide protection against inhalational anthrax.
The US Department of Health and Human Services has stocked millions of doses of BioThrax TM for emergency preparedness against bioterrorism. In addition, the US Department of Defense has a mandatory program to immunize active duty service personnel against anthrax. The current immunization program with BioThrax TM requires multiple injections by trained personnel. Therefore, considerable medical resources need to be devoted to the immunization program, especially in the case of a mass immunization against potential bioterrorism attack. This makes it difficult for the compliance of the immunization program and underscores the need for development of alternative and optimized vaccination protocols. Recently, Kenny et al. demonstrated that a needle-free transcutaneous immunization (TCI) with recombinant PA plus the heat-labile toxin of Escherichia coli protects mice against inhalational anthrax [29] . Current study has shown that a mucosal immunization protocol provides an alternative for immunization against anthrax. Since the anthrax vaccine can be reformulated into a nasal spray or skin patch, self-administration of the vaccine becomes possible. These will be simple and more comfortable ways for administration of the vaccine.
The research reported here is a proof of concept that an alternative human immunization strategy against anthrax is possible. Our next steps will be to study the duration of the protective immunity elicited by mucosal immunization in comparison with injection and assess antibody responses in bronchoalveoar lavages (BALs). We will also determine if intranasal immunization with BioThrax TM can protect against inhalational anthrax using guinea pig and nonhuman primate models. In addition, potential side effects of intranasal immunization with BioThrax TM will also need to be addressed. If further studies in animal models are encouraging, we will pursue a clinical trial to determine if humans can be immunized with BioThrax TM by needle-free intranasal mucosal administration.
